FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a pharmaceutical combination for treating blood cancer, which includes a histone deacetylase (HDAC) inhibitor of chemical formula 1, a proteasome inhibitor or an immunomodulatory drug and an anticancer steroid agent.
EFFECT: pharmaceutical combination of the present invention can be useful in treating blood cancer, for example, multiple myeloma, by reducing toxicity, which is a drawback of standard HDAC inhibitors, and an equivalent level of pharmacological action provided by a complex cancer growth inhibition mechanism, which is mediated by a compound with chemical formula 1 and its pharmaceutically acceptable salt, proteasome inhibitor or immunomodulatory drug and anti-cancer steroid agent.
11 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| COMBINATIONS OF SPECIFIC CLASS I HISTONE DEACETYLASE INHIBITORS AND PROTEASOME INHIBITORS | 2007 |
|
RU2456990C2 |
| DOSES OF PANOBINOSTAT FOR MULTIPLE MYELOMA | 2016 |
|
RU2729425C2 |
| SYNERGIC COMBINATION OF PROTEASOME INHIBITOR AND VITAMIN K FOR INHIBITION OF GROWTH AND PROLIFERATION OF TUMOUR CELLS, PHARMACEUTICAL COMPOSITION AND THEREOF-BASED ANTI-TUMOUR MEDICATION | 2013 |
|
RU2563986C2 |
| COMPOSITIONS COMPRISING ANTIBODY TO CD38 AND CARFILZOMIB | 2014 |
|
RU2670127C2 |
| COMPOSITIONS COMPRISING CD38 ANTIBODIES AND CARFILZOMIB | 2014 |
|
RU2723937C2 |
| APPLICATIONS OF IMMUNOCONJUGATES WITH CD138 AS TARGET | 2010 |
|
RU2561041C2 |
| METHOD OF TREATING MULTIPLE MYELOMA | 2009 |
|
RU2519750C2 |
| COMPOSITIONS AND METHODS FOR TREATING DISEASE | 2007 |
|
RU2482877C2 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
